Gastric aspirate shake test for predicting of surfactant therapy in premature neonates with gestational age ≤ 34W with hyaline membrane disease

Document Type : Research Paper


1 Associate Professor of Neonatal-Perinatal Medicine,Department of Pediatrics, School of Medicine Amir al momenin Hospital,Zabol university of medical sciences,Zabol,Iran

2 Assistant Professor of Pediatrics,Department of Pediatrics, School of Medicine,Amir al momenin Hospital,Zabol university of medical sciences,Zabol,Iran

3 Instructor of Medical Education,Department of Community Medicine, School of Medicine Zabol university of medical sciences,Zabol,Iran


Introduction: Hyaline membrane disease (HMD) is one of the most common respiratory diseases in preterm infants. The main cause of the disease is surfactant deficiency and its clinical symptoms include respiratory distress tachypnea, cyanosis, granulation, and increased oxygen demand. There are generally two methods of administering surfactants, 1- prophylactic 2- Rescue. This study aimed to evaluate the effect of gastric aspiration impulse test on predicting the need for surfactant in neonates.
Materials and methods: This study was a descriptive-analytic study in which all newborn infants less than or equal to 34 weeks of age had respiratory distress and clinical symptoms of hyaline membrane disease such as granitic, cyanosis, intraretinal retraction. And sub-ribs were studied and causes other than those listed are exclusion criteria and excluded. The sampling method was easy and data were collected from an oral interview of pregnant mothers, checking the files and completing the questionnaire. Data analysis software was SPSS v21 and descriptive statistics and regression tests were used for odds ratios.
Result: In this study, 62 (68.1%) neonates were male and 29 (31.9%) were female. The mean birth weight of neonates was 1662±593 g and their mean age was 31.7±2.5 weeks. Normal delivery and cesarean section in this study were 35 (38.5%) and 56 (61.5%), respectively. According to the findings, diabetes mellitus had a significant relationship with hyaline membrane disease. Hypertension, addiction, corticosteroid administration, and gender were also significantly associated with membrane disease (P <0.05). According to the present study, there was no significant relationship between the type of delivery and hyaline membrane disease (P> 0.05).
Conclusion: Our study showed that the offspring of mothers with hypertension, addiction, and diabetes were less likely than others to have membrane disease and need to be given surfactants. The administration of corticosteroid drugs to mothers is also associated with the development of hyaline membrane disease.


1.Stoll BJ, Kleigman MR. Respiratory tract disorder. In: Behrman RE, Kliegman R, Jenson HB, Editors.
Nelson textbook of pediatrics. Philadelphia: WB. Saunders; 2004. p. 496-510.
2.Rodriguez RJ, Martin RJ, Fanaroff AA. Respiratory distress syndrome and its management. In: Fanaroff
AA, Martin RJ, Walsh MC, Editors. Neonatal-perinatal medicine – diseases of the fetus and infant.
Philadelphia: Mosby; 2006. p. 1097-107.
3.Suresh GK, Soll RF. Pharmacologic adjuncts II: exogenous surfactants. In: Goldsmith JP ,Karotkin E,
Editors. Assisted ventilation of the neonate. Philadelphia: WB. Saunders; 2003. p. 330-44.
4.Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality
in preterm infants. Cochrane Database Syst Rev 2001; (2): CD000510.
5.Spafford PS, Kendig JW, Maniscalco WM. Use of natural surfactants to prevent and treat respiratory
distress syndrome. Semin Perinatol 1993; 17(4): 285-94.
6.Kattwinkel J. Surfactant. Evolving issues. Clin Perinatol 1998; 25.23-11 :)1(
7.Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks
gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group. Online J
Curr Clin Trials 1992; Doc No 28.2883 :
8.Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, et al. Prophylactic administration of
calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in
neonates of 29 through 32 weeks' gestation. Pediatrics 1993; 92(1): 90-8.
9.Andersen T, Holm HS, Kamper J. [Surfactant treatment of newborn infants receiving continuous positive
airway pressure treatment]. Ugeskr Laeger 2006; 168(43): 3723-7.
10.Reininger A, Khalak R, Kendig JW, Ryan RM, Stevens TP, Reubens L, et al. Surfactant administration
by transient intubation in infants 29 to 35 weeks' gestation with respiratory distress syndrome decreases the
likelihood of later mechanical ventilation: a randomized controlled trial. J Perinatol 2005.8-102 :)11(32 ;
11.Skelton R, Jeffery H. "Click test": rapid diagnosis of the respiratory distress syndrome. Pediatr Pulmonol
1994; 17(6): 383-9.
12.Chaudhari R, Deodhar J, Kadam S, Bavdekar A, Pandit A. Gastric aspirate shake test for diagnosis of
surfactant deficiency in neonates with respiratory distress. Ann Trop Paediatr 2005; 25(3): 205-9.
13.Matti P, Pistoia L, Fornale M, Brunn E, Zardini E. Prevalence of RDS in diabetic pregnancy. Minerva
ginecologica. 1996;48(10):409-13.
14.Niesłuchowska-Hoxha A, Cnota W, Czuba B, Ruci A, Ciaciura-Jarno M, Jagielska A, et al. A
Retrospective Study on the Risk of Respiratory Distress Syndrome in Singleton Pregnancies with Preterm
Premature Rupture of Membranes between 24. BioMed research international. 2018;2.018
15.Li Y, Wang W, Zhang D. Maternal diabetes mellitus and risk of neonatal respiratory distress syndrome: a
meta-analysis. Acta Diabetologica. 2019;56(7):729-40.
16.Kawakita T, Bowers K, Hazrati S, Zhang C, Grewal J, Chen Z, et al. Increased neonatal respiratory
morbidity associated with gestational and pregestational diabetes: a retrospective study. American journal of
perinatology. 2017;34(11):1160-8.
17.Becquet O, El Khabbaz F, Alberti C, Mohamed D, Blachier A, Biran V, et al. Insulin treatment of
maternal diabetes mellitus and respiratory outcome in late-preterm and term singletons. BMJ open.
18.Tubman T, Rollins M, Patterson C, Halliday H. Increased incidence of respiratory distress syndrome in
babies of hypertensive mothers. Archives of disease in childhood. 1991;66(1 Spec No):52-4.
PREMATURE INFANTS. Pediatrics. 1972;50(4):515-25.
20.Mehrpisheh S, Mosayebi Z, Memarian A, Kadivar M, Nariman S, Ostadrahimi P, et al. Evaluation of
specificity and sensitivity of gastric aspirate shake test to predict surfactant deficiency in Iranian premature
infants. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health.
21.Kim JH, Lee SM, Lee YH. Risk factors for respiratory distress syndrome in full-term neonates.
Yeungnam University Journal of Medicine. 2018;35(2):187-91.
22.Wang J, Yan J, Han J, Ning Y ,Yan C. Risk factors for respiratory distress syndrome among Chinese
infants of 34-42 weeks gestational age: a multi-center observational study. Int J Clin Exp Med.
23.Liu J, Yang N, Liu Y. High-risk factors of respiratory distress syndrome in term neonates: a retrospective
case-control study. Balkan medical journal. 2014;2014(1):64-8.
24.NIELSEN HC, TORDAY JS. Sex differences in avian embryo pulmonary surfactant production:
evidence for sex chromosome involvement. Endocrinology. 1985.1-21:)1(111;
25.Seaborn T, Simard M, Provost PR, Piedboeuf B, Tremblay Y. Sex hormone metabolism in lung
development and maturation. Trends in Endocrinology & Metabolism. 2010;21(12):729-38.
26.Nielsen HC. Androgen receptors influence the production of pulmonary surfactant in the testicular
feminization mouse fetus. The Journal of clinical investigation. 1985;76(1):177-81.
27.Bresson E, Seaborn T, Côté M, Cormier G, Provost PR, Piedboeuf B, et al. Gene expression profile of
androgen modulated genes in the murine fetal developing lung. Reproductive Biology and Endocrinology.
28.Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory morbidity in term infants
delivered by elective caesarean section: cohort study. Bmj. 2008;336.1-82:)1322(
29.Chaudhari R, Deodhar J, Kadam S, Bavdekar A, Pandit A. Gastric aspirate shake test for diagnosis of
surfactant deficiency in neonates with respiratory distress. Annals of tropical paediatrics. 2005;25(3):205-9.
30.McGinnis MR. Laboratory handbook of medical mycology: Elsevier; 2012.
31.Chander J. Textbook of medical mycology: JP Medical Ltd; 2017.
32.Amoa AB, Paiva M, Klufio C. Antepartum prediction of respiratory distress syndrome: a comparison of
the shake test, the tap test and the turbidity test. Papua and New Guinea medical journal. 2003;46(1-2):32-40.
33.Babaei H, Sadeghi N, Rezaei M. Comparative study of diagnostic value of gastric aspirate shakes test &
lamellar body count for prediction of lung maturity in premature neonates .Scientific Journal of Kurdistan
University of Medical Sciences. 2013;18(4):8-17.
34.NooriShadkam M, Lookzadeh MH, Taghizadeh M, Golzar A, NooriShadkam Z. Diagnostic value of
gastric shake test for hyaline membrane disease in preterm infant. Iranian journal of reproductive medicine.
35.Mohammadi M, Iranpour R, Mohammadi zadeh M, Soleimani B, Heidari MH. Evaluation of Gastric
aspirate shake test in predicting need for surfactant in neonates with hyaline membrane disease. Journal of
Isfahan Medical School. 2010;27(96):306.
36.Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ: British Medical Journal.